BioNxt Solutions Inc. (CVE:BNXT) | Finanzwire

Basculer en Français

10597	Companies
224768	Keywords
153494	Articles
118907	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

BRIEF

published on 06/15/2026 at 09:50, 3 days 8 hours ago

BioNxt Advances Commercialization for Patented Multiple Sclerosis Treatment

Business Development Multiple Sclerosis Cladribine BioNxt Solutions BNT23001
PRESS RELEASE

published on 06/15/2026 at 09:45, 3 days 8 hours ago

BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF
BioNxt Solutions Inc. partners with a BD&L advisor to commercialize BNT23001, a sublingual Cladribine ODF for MS. Preparing for a human bioavailability study

BioNxt Solutions Inc. Commercialization BNT23001 Bioavailability Study BD&L Advisor
BRIEF

published on 06/12/2026 at 23:20, 5 days 18 hours ago

BioNxt Solutions Inc. Announces Private Placement Initiative

Private Placement Stock Warrants BioNxt Solutions R&D Funding European Operations
PRESS RELEASE

published on 06/12/2026 at 23:15, 5 days 19 hours ago

BioNxt Announces Non-Brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
BioNxt Solutions Inc. announces non-brokered private placement of units at $0.33 per Unit with maximum gross proceeds of $2,000,000. Offering includes common shares and purchase warrants

Private Placement Common Shares BioNxt Solutions Inc. LIFE Offering Purchase Warrants
BRIEF

published on 06/11/2026 at 00:35, 7 days 17 hours ago

BioNxt Solutions Inc. Extends Convertible Debentures and Issues Warrants

Warrants Convertible Debentures Regulatory Approval Securities Legislation BioNxt Solutions
PRESS RELEASE

published on 06/11/2026 at 00:30, 7 days 17 hours ago

BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants
BioNxt Solutions Inc. announces amendment of terms for unsecured convertible debentures, extending maturity dates and issuing common share purchase warrants. For further details, visit bionxt.com

BioNxt Solutions Inc. Common Share Purchase Warrants Regulatory Approvals Debentures Maturity Dates
BRIEF

published on 05/19/2026 at 09:10, 30 days 9 hours ago

BioNxt Progresses in Semaglutide Oral Dissolvable Film Development

Pharmaceutical Development BioNxt Solutions GLP-1 Therapies Sublingual Drug Delivery Semaglutide ODF
PRESS RELEASE

published on 05/19/2026 at 09:05, 30 days 9 hours ago

BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development
BioNxt Solutions Inc. announces advancement of Semaglutide oral dissolvable film program into active pharmaceutical development phase, targeting growing GLP-1 market. Company leverages expertise in drug delivery systems for chronic diseases

BioNxt Solutions Inc. Oral Dissolvable Film Drug Delivery Systems Semaglutide GLP-1 Market
BRIEF

published on 04/28/2026 at 09:10, 1 month 20 days ago

BioNxt Explores Psychedelic Drug Delivery Advances

Drug Delivery Technology Mental Health Treatments BioNxt Solutions Regulatory Developments Psychedelic Therapeutics
PRESS RELEASE

published on 04/28/2026 at 09:05, 1 month 20 days ago

BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum
BioNxt Solutions Inc. is exploring applying its drug delivery tech to psychedelic therapeutics amid global momentum. Market opportunity in mental health treatments highlighted

BioNxt Solutions Inc. Mental Health Disorders Drug Delivery Technologies Psychedelic Therapeutics Advanced Drug Delivery

Accesswire

Published on 06/18/2026 at 18:00, 19 minutes ago

BEACN Closes Second Series Under Loan Program and Previews BEACN App Version 1.4
Published on 06/18/2026 at 17:30, 49 minutes ago

Sekur Private Data Appoints Nathan R. Price as Special Advisor for Diplomacy & Intelligence
Published on 06/18/2026 at 15:50, 2 hours 29 minutes ago

Pentagon I Capital Corp. and Prospectiva Resources Ltd. Announce Financing
Published on 06/18/2026 at 15:00, 3 hours 19 minutes ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention
Published on 06/18/2026 at 14:30, 3 hours 49 minutes ago

Voting Results from Solitario Resources Corp Annual Meeting Held June 17, 2026

View all ACCESSWIRE

EQS Group

Published on 06/18/2026 at 17:45, 34 minutes ago

2CRSi SA: 2CRSi disputes the content of the document published by Grizzly Research and is preparing a substantiated response calling for the suspension of trading in its shares
Published on 06/18/2026 at 17:40, 39 minutes ago

REINET INVESTMENTS S.C.A. ANNOUNCES SHARE BUYBACK PROGRAMME
Published on 06/18/2026 at 17:36, 43 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 06/18/2026 at 17:30, 49 minutes ago

Amundi Physical Metals plc: Final Terms
Published on 06/18/2026 at 17:25, 54 minutes ago

Geely Farizon Green Smart Mobility Solution Debuts at 2026 Hong Kong Expo

Les Echos

Published on 06/18/2026 at 18:00, 19 minutes ago

Outstanding shares and voting rights statement at 31 May 2026
Published on 06/18/2026 at 17:45, 34 minutes ago

EURAZEO INVESTS IN LAURALU, A PAN-EUROPEAN PROVIDER OF DEPLOYABLE INDUSTRIAL INFRASTRUCTURE
Published on 06/18/2026 at 17:38, 41 minutes ago

Statement of transactions in own shares from June 8, 2026 to June 12, 2026
Published on 06/18/2026 at 13:00, 5 hours 19 minutes ago

Edenred statement
Published on 06/18/2026 at 09:06, 9 hours 13 minutes ago

Eiffage, member of the NSORe joint venture, wins the contract for a converter station for the NSC2 offshore grid connection project in Germany

View all LES ECHOS COMFI WIRE